Business Context and Reporting Period
Company: Hyseq, Inc. (Note: Request metadata listed "Oruka Therapeutics," but the filing text identifies the registrant as Hyseq, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1998
Business Overview: Hyseq applies proprietary DNA array technology (HyX Platform) to develop gene-based therapeutic candidates and diagnostic products. The company maintains a large proprietary database of partial human gene sequences (HyGenomics Database). Key collaborations include Chiron Corporation (therapeutics/diagnostics) and Perkin-Elmer (commercialization of HyChip products).
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Revenue | $2,683,000 | $272,000 |
| Operating Expenses | $6,171,000 | $2,237,000 |
| Net Loss | $(2,689,000) | $(1,916,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.43) |
| Cash & Cash Equivalents | $32,671,000 | $4,743,000 |
| Short-Term Investments | $22,860,000 | $0 |
| Total Current Assets | $56,577,000 | $N/A |
| Total Current Liabilities | $3,424,000 | $N/A |
| Accumulated Deficit | $(17,438,000) | $(14,749,000) |
Liquidity: As of March 31, 1998, the company held $55.5 million in cash, cash equivalents, and short-term investments, plus $2.1 million in restricted cash. Management expects existing resources to fund operations through 1999.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased to $2.7 million from $272,000. This is primarily due to minimum research payments from the Chiron collaboration, recognized ratably. The prior year revenue was derived from a completed NIST grant.
- Expense Growth: Operating expenses rose to $6.2 million from $2.2 million. Research and Development (R&D) expenses jumped to $4.1 million (from $1.3 million) due to scaling gene sequencing capacity (from 1M sequences/month), adding scientific personnel, and IP protection costs. General and Administrative (G&A) expenses increased to $2.1 million (from $0.9 million) due to marketing, staffing, and legal fees related to patent litigation.
- Interest Income: Net interest income increased significantly to $799,000 (from $49,000) due to higher cash balances resulting from the 1997 IPO and private placements.
- Cash Flow: Net cash used in operating activities improved significantly, decreasing to $173,000 (from $1.7 million usage) due to revenue recognition from the Chiron deal. Investing activities provided $9.6 million net cash due to maturities of short-term investments exceeding purchases and capital expenditures.
Outlook, Risks, and Contingencies
- Outlook: The company expects to incur operating losses at least through 1999. Future revenue depends on maintaining existing collaborations (Chiron, Perkin-Elmer) and securing new partners. There is no assurance of achieving profitable operations.
- Legal Proceedings: Hyseq is engaged in two patent infringement lawsuits against Affymetrix, Inc. (filed March 1997 and December 1997) regarding SBH technology. The company seeks injunctions and damages, while Affymetrix has counterclaimed for patent invalidity. Legal expenses are expected to increase over the next year.
- Commitments: Under the Perkin-Elmer agreement, Hyseq is obligated to spend an aggregate of $5.0 million through May 1999 on HyChip development. Approximately $2.2 million has been spent to date.
- Risks: Key risks include the inability to secure new collaboration partners, failure to obtain regulatory approvals, the outcome of patent litigation, and the high cost of scaling sequencing operations without corresponding revenue.
Investor Verification Checklist
- Collaboration Sustainability: Verify the terms and renewal status of the Chiron and Perkin-Elmer agreements, as they are the primary revenue drivers.
- Legal Exposure: Monitor the status of the Affymetrix litigation, as a loss could invalidate core patents and increase legal costs significantly.
- Burn Rate vs. Runway: Confirm that the $55.5 million cash position is sufficient to cover the projected $5.0 million commitment to Perkin-Elmer and ongoing R&D scaling through 1999.
- Revenue Recognition: Understand the ratable recognition model for Chiron payments to anticipate potential quarterly revenue fluctuations.